4 Cannabis Stocks with Great International Growth Prospects

The cannabis stocks on our list have positioned themselves for explosive growth in untapped markets overseas

SmallCapPower | August 20, 2018: Today we have identified four cannabis stocks that have secured partnerships with overseas agencies for international distribution. With Canadian market share being dominated by major players such as Canopy Growth (TSX:WEED, NYSE:CGC), these companies are poised to grow revenue by supplying international markets.

For Our Complete Coverage Of Canadian Marijuana Stocks Click Here    

Watch: Cannex Capital Holdings (CSE:CNNX) Wants to Emerge as a Multi-State U.S. Player, Says CEO 

Tilray Inc. (NASDAQ:TLRY) – $29.27
Pharmaceuticals

Tilray is a global leader in medical cannabis research, cultivation, and distribution. Tilray was one of the first companies to have its facility certified by the European Medicinal Agency (EMA) as Good Manufacturing Practices (GMP) compliant, allowing it to distribute its products within Europe. The Company currently services thousands of medical clients across Australia, New Zealand, Germany, Portugal and Germany. On August 1, 2018, Tilray announced that its Tilray 2:100 product had shown promising results for children with drug-resistant epilepsy in a Phase II study conducted by Toronto’s Sick Kids Hospital.

  • Market Cap: $2,686.8 Million
  • Average Volume last 30 days: 612,386

Cronos Group Inc. (TSX:CRON) – $8.51
Pharmaceuticals

Cronos Group owns and operates two licensed producers of medical marijuana in Canada: Peace Naturals and Original BC. Cronos plans to ramp up production at its Peace Naturals facility from the existing 5,000 kg to 40,000 kg before 2019. Internationally, the Company formed a partnership with Israeli entity, Gan Shmuel, to set up a low-cost production facility in Israel. The proposed facility is expected to produce 24,000 kg/year.

  • Market Cap: $1,510.0 Million
  • Average Volume last 30 days: 406,698

Emblem Corp. (TSXV:EMC) – $1.17
Pharmaceuticals

Emblem is a licensed producer of medical marijuana under the ACMPR. The Company, lead by former healthcare & pharma executives, currently produces 2,000 kg/yr of dried cannabis and plans to add a further 15,000 kg/yr by Q1/2019. On June 20, 2018, Emblem announced the formation of a joint venture with German pharmaceutical wholesaler Ancos Pharma GmbH under the name “Emblem Germany,” allowing the Company to export cannabis products into Germany. Under this agreement Emblem would hold 60% ownership of Emblem Germany and Acnos would own the remaining 40%.

  • Market Cap: $140.7 Million
  • Average Volume last 30 days: 275,799

Khiron Life Sciences Corp. (TSXV:KHRN) – $0.98
Pharmaceuticals

Khiron Life Sciences is a Canadian medical cannabis company with operations in Columbia. The Company is focused on scientific and medical-based research applications for cannabis. It describes itself as a “plant to patient” company – selecting seeds, investing in R&D and engaging with doctors. Khiron estimates a potential market of 6M patients in Columbia, with the intention of targeting an estimated 68M patients throughout Latin America upon future expansion. In 2017, Khiron was granted cultivation and production licenses in Columbia for both low and high THC strains. It intends to open its first clinics in Q4/2018.

  • Market Cap: $45.9 Million
  • Average Volume last 30 days: 209,925

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below: